Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

NCT00777764 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00777764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00777764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2008
Completion date
April 30, 2009
Enrollment
60 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, healthy